SCHEMBL7689036

SCHEMBL7689036

CCc1ncc2sccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 11/20 0.46
ADORA1 P30542 10/20 0.46
ADORA2B P29275 2/20 0.46
ADORA3 P0DMS8 1/20 0.46
PDE4A P27815 4/20 0.39
PDE4B Q07343 4/20 0.39
PDE4C Q08493 4/20 0.39
PDE4D Q08499 4/20 0.39
PDE3B Q13370 4/20 0.39
PDE3A Q14432 4/20 0.39
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
PPARG P37231 1/20 0.36
HTT P42858 1/20 0.36
NCOA2 Q15596 1/20 0.36
NCOA1 Q15788 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NCOA3 Q9Y6Q9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6216159 0.86 ADORA2A (0.38) ADORA2AADORA1ADORA2BADORA3PDE4A
SCHEMBL4314961 0.82 PDE4A (0.43) ADORA2AADORA1ADORA2BADORA3PDE4A
SCHEMBL5113214 0.81 KDM4E (0.36) ADORA2AADORA1ADORA2BADORA3KDM4E
SCHEMBL27630537 0.76 PDE4A (0.49) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL28654885 0.75 PDE4A (0.50) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL2162809 0.75 KDM4E (0.41) ADORA2AADORA1KDM4EALDH1A1MAPT
SCHEMBL30637303 0.75 KDM4E (0.41) ADORA2AADORA1KDM4EALDH1A1MAPT
SCHEMBL12343963 0.72 ADORA2A (0.37) ADORA2AADORA1ADORA2BADORA3PDE4A
SCHEMBL358864 0.71 ADORA2A (0.42) ADORA2AADORA1KDM4EALDH1A1MAPT
SCHEMBL996451 0.71 ADORA2A (0.42) ADORA2AADORA1KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6339089-B2 ANTIHYPOXIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; VASOCONSTRICTION; REDUCES BLOOD PARTIAL PRESSURE OF CARBON DIOXIDE; RESPIRATORY DISORDERS; UNDER OXYGEN INHALATION TREATMENT FUJIREBIO INC. (JP) 2002-01-15 US disclosed